Concordance between clinical presentation and histopathological staging canine mammary tumors

• Alicia Decuadro Veterinary Faculty Hospital. Montevideo, Uruguay
• Alejandro Benech Veterinary Faculty Hospital. Montevideo, Uruguay
• Silvia Llambi Genetics and animal improvement Unit, Veterinary Faculty. Montevideo, Uruguay
• Rosa Gagliardi † Genetics and animal improvement Unit, Veterinary Faculty. Montevideo, Uruguay

DOI: https://doi.org/10.52973/rcfcv-e33244

Keywords: Canine mammary tumors, mammary tumor histopathology, clinical staging in mammary tumors

Abstract

In this work it was examined the concordance between clinical staging and histopathological staging of mammary tumors in 32 female dogs. It was observed that the average age of presentation of the pathology was 9 years (ranged from 6 to 12 years). The most affected mammary glands were the caudal abdominal and the inguinal, 20 out of 32 female dogs had multiple tumors (62%), and 38% single tumors. Regarding the breeds, the most frequent ones were mixed breeds, Poodle, Cimarron (native breed of Uruguay) and Labrador Retriever. Of the 32 female dogs with breast tumors studied, 65% had histopathological diagnosis of malignant tumor, while 35% had benign tumors. Clinical staging data showed that 64% of the cases with benign tumors were in stage I (1 to 3 cm) and 36% were in stage II (3 to 5 cm). Among those diagnosed with malignant tumors, 10% were in stage V, 57% in stage III, 9% in stage II, and 24% in stage I. There were no animals in stage IV. The most frequently found malignant tumors were tubular carcinoma and complex carcinoma, followed by solid and tubulopapillary carcinomas. Within the benign tumors, complex adenoma was the most frequent, followed by benign mixed tumor and simple ductal papilloma. The concordance between clinical staging and histopathology was low, as we could observe both benign T2 (3 to 5 cm) and malignant T1 (1 to 3 cm) tumors.

References

Sorenmo K, Shofer F, Goldschmidt M. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J. Vet. Int. Med. 2000; 14:266–270.

Hermo G, García M, Torres P, Gobello C. Tumores de mama en la perra. Cien. Vet. 2005; 7(1):1–25.

Ochiat K, Ishiguro–Oonuma T, Yoshikawa Y, Udagawa C, Kato Y, Watanabe M, Bonkobara M, Morimatsu M, Toshinori. B. Polymorphisms of canine BRCA2 BRC repeats affecting interaction with RAD51. Biomed. Res. (Tokyo) 2015; 36 (2):155–158.

Al–Dissi A, Haines D, Singh B, Kidney B. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor–2 in canine simple mammary gland adenocarcinomas. Canad. Vet. J. 2010; 51:1109–1114.

Paoloni M, Khanna C. Comparative Oncology Today. Vet. Clin. North America: Small Anim. Pract. 2007; 37(6):1023–32.

Sobral R, Honda S, Katayama M, Brentani H, Brentani M, Patrão D, Folgueira M. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSSI I, MTSS I, CLPTM I and PRSSI I, MTSS I, SMYD2 in canine mammary gland cancer. Acta Vet. Scandinavica. 2008; 50:27.

Liu D, Xiong H, Ellis A, Northrup N, Rodriguez C, O'Regan R, Dalton S, Zhao S. Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. Cancer Res. 2014; 74 (18):5045–56.

Ruthanne C, Garret L. Tumores genitourinarios y de glándula mamaria. En: Ettinger, S, Feldman, E (eds.). Tratado de Medicina Interna Veterinaria, enfermedades del perro y el gato. 6ta. Ed. Volumen 1. Madrid. Ed. Elsevier. 2007; p 784 –789.

Lana, S. Tumores de glándula mamaria. En: Withrow, S., Macewen, S.(eds.) Oncología clínica de pequeños animales, 4ª. ed. Multimedica. 2008; p. 605– 620.

Rivera P, Melin M, Biagi T, Fall T, Häggström J, Lindblad–Toh K, von Euler H. Mammary Tumor Development in Dogs Is Associated with BRCA1 and BRCA2. Cancer Res. 2009; 69:8770–8774.

Ogilvie G, Moore A. Neoplasia mamaria. En: Ogilvie GK., Moore A.S. (eds.). Manejo del paciente canino oncológico. United States, Intermédica. 2008; p 675 – 687.

Owen L. A comparative study of canine and human breasy cancer. Invest. Cell Pathol. 1979; 2:257 – 275.

Cassali G, Bertagnolli A, Lavalle G, Tavares W, Ferreira E, Campos C. Perspectives for diagnosis, prognosis and treatment of mammary neoplasias in dogs. 34th World Small Animal Veterinary Congress – WSAVA. 07/21–24, São Paulo. 2009; p 680–682.

Vail D, Thamm D, Liptak J. Withrow & MacEwen’s Small Animal Clinical Oncology, 6a. ed., cap.28 Tumors of the mammary gland. Ed. Elsevier. 2020; p 604–625.

Misdorp W, Else R, Hellmen E, Lipscomb T. Histological classification of mammary tumours of the dog and the cat. International Histological Classification of Tumours of Domestic Animals, 2nd. Series. Bulletin of the World Health Organization/American Registry of Pathology. 1999; p 18–25.

Goldschmidt M, Peña L, Rasotto R, Zapulli V. Classification and grading of canine mammary tumors. Vet. Pathol. 2011; 48:117–131.

Rasotto R, Berlato D, Goldschmidt MH, Zappulli V. Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases. Vet. Pathol. 2017; 54:571–578.

Elston C, Ellis I. Assessment of histological grade. Eds. Systemic Pathology. The breast. London: Churchill Livingstone. 1998; p 365–84.

Cassali GD, Jark PC, Gamba C, Damasceno KA, Estrela–Lima A, Nardi AB de, Ferreira E, Horta RS, Bruna F, Sueiro FAR, Rodrigues LCS, Nakagaki KYR. Consensus Regarding the Diagnosis, Prognosis and Treatment of Canine and Feline Mammary Tumors – 2019. Braz. J. Vet. Pathol. 2020; 13(3): 555 – 574. doi: https://doi.org/kghx

Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: Application of a human grading method. J..Comp. Pathol. 2005; 133:246–252.

Cohen J. Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol. Bull. 1968; 70(4):213–20.

Queiroga F, Raposo T, Carballo M, Prada J, Pires I. Canine mammary tumours a model to study human breast cancer: Most recent findings. In vivo. 2011; 25(3):455–465.

Burrai G. Gabrieli A, Moccia V, Zappulli V, Porcellato I, Brachelente C, Pirino S, Polinas M, Antuofermo EA. Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study. Anim. 2020; 10(9):1687. doi: https://doi.org/kghz

Kurzman I, Gilbertson S. Prognostic factors in canine mammary tumors. Semin. Vet. Med. Surg. (Small Animal). 1986; 1:25–32.

Egenvall A, Bonnett B, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Preven. Vet. Med. 2005; 69:109–127.

Zatloukal J, Lorenzová J, Tichy F, Neâas A, Kecová H, Kohout P. Breed and Age as Risk Factors for Canine Mammary Tumours. Acta Vet. Brno. 2005; 74:103–109.

Benavente M, Bianchi C, Aba M. Canine mammary tumors: risk factors, prognosis and treatments. J. Vet. Adv. 2016; 6(8):1291–1300.

Ferreira E, Bertagnnolli A, Cavalcanti M, Schmitt F, Cassli G. The relationship between tumor size and expression of prognostic markers in benign and malignant canine mammary tumors. Vet. Comp. Oncol. 2009; 193:1–6.

Hellmén E, Bergstrom R, Holmberg L, Spangberg I, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet. Pathol. 1993; 30:20–27.

Camargo F, Araújo K., Bonolo C, Cavalheiro A, Lavalle, G. Cassali, G. Mixed tumors of the canine mammary glands: Evaluation of prognostic factors, treatment, and overall survival. Vet. Anim. Sci. 2018; 7: e100039. doi: https://doi.org/kgh2

Sorenmo K, Rasotto R, Zappulli V, Goldschmidt M. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet. Pathol. 2011; 48:85–97.